European Journal of Obstetrics & Gynecology and Reproductive Biology
Full length articleEvaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use☆
Introduction
To reduce the incidence of unintended pregnancy, clinical practice guidelines advocate the use of long-acting reversible contraception (LARC): highly effective methods independent of user compliance [1], [2], [3], [4]. Levonorgestrel intrauterine systems (LNG-IUSs) are a subset of LARC; available versions include: LNG-IUS 8 (Jaydess®/Skyla®; Bayer HealthCare) [5] and LNG20 (Levosert™/Liletta™; Medicines360/Actavis) [6], which are currently indicated for contraception for up to 3 years, and LNG-IUS 20 (Mirena®; Bayer HealthCare) [7], which is approved for up to 5 years of use for contraception.
A new LNG-IUS (LNG-IUS 12) has been developed for up to 5 years of use with an average release rate of ∼12 μg/24 h over the first year. LNG-IUS 12 has a narrower hormone reservoir, and smaller T-frame (28 × 30 mm) compared with LNG-IUS 20 and LNG20. Consequently, LNG-IUS 12 is placed using a narrower placement tube, which is equivalent in diameter to the placement tube used for LNG-IUS 8 [8], [9], [10]. Smaller placement systems may be more suitable for women with a narrower cervical canal and/or smaller uterine cavity, such as nulliparous women. This may broaden the appeal of LNG-IUSs to a wider range of women and help increase LARC uptake.
This article reports the final results of a 5-year Phase III trial evaluating the efficacy and safety of LNG-IUS 12 in nulliparous and parous women.
Section snippets
Materials and methods
This randomized, open-label, double-arm Phase III study (clinicaltrials.gov: NCT00528112) was conducted at 138 centers in 11 countries. It was originally designed as a 3-year study, and women who met eligibility criteria were randomized 1:1 to use either LNG-IUS 8 or LNG-IUS 12 for 3 years. Preliminary results showed that the efficacy of LNG-IUS 8 was well within the acceptable range over 3 years. Additionally, pharmacokinetic (PK) modeling predicted that LNG release rates with LNG-IUS 12 at
Results
Between August 2007 and May 2008, 2885 women were randomized and 1453 were allocated to LNG-IUS 12 (Fig. 1). The FAS included 1452 women for whom placement was attempted. Placement was successful in 1445/1452 women (99.5%), with no difference in success rates between nulliparous and parous women. Baseline characteristics were similar between women in the FAS and those who entered the extension period (Table 1).
The unadjusted 5-year PI was 0.29; PIs in each individual year were equal to or less
Discussion
In this study in nulliparous and parous women, LNG-IUS 12 was shown to be a highly effective contraceptive method for up to 5 years of use. Consistent contraceptive efficacy was observed over time, as demonstrated by the continuously low unadjusted PIs for each year. The efficacy of LNG-IUS 12 (5-year cumulative failure rate of 1.45%) was similar to that of the higher-dose LNG-IUS 20 (0.7% at 5 years) [7], which is indicated for up to 5 years of contraceptive use [7].
LNG-IUS 12 was well
Financial disclosure
Study funded by Bayer HealthCare. Medical writing support funded by Bayer HealthCare.
Condensation
LNG-IUS 12 is a highly effective low-dose intrauterine system with a favorable safety profile providing 5 years of contraception to parous and nulliparous women.
Acknowledgments and disclosures
Medical writing support was provided by Paul Richard Wilson, Helen Attisha, and Laura Miller of Chameleon Communications, with the financial support of Bayer HealthCare.
Kristina Gemzell-Danielsson serves on advisory boards and has been an invited speaker at scientific meetings for Bayer AG, MSD/Merck, HRA Pharma, Exelgyn, and Gedeon Richter on an ad hoc basis. Her institution has received grants for conducting the Phase II and Phase III clinical trials of LNG-IUS 8 and LNG-IUS 12. Dan Apter’s
References (21)
- et al.
Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system
Contraception
(2015) - et al.
Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial
Contraception
(1994) - et al.
Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T
Contraception
(1992) - et al.
Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices
Am J Obstet Gynecol
(1992) - et al.
Fertility after discontinuation of contraception: a comprehensive review of the literature
Contraception
(2011) American College of Obstetricians and Gynecologists ACOG Practice Bulletin No. 121: Long-acting reversible contraception: implants and intrauterine devices
Obstet Gynecol
(2011)- National Institute for Health and Clinical Excellence Long-acting reversible contraception: the effective and...
- World Health Organization Medical eligibility criteria for contraceptive use: fifth edition. 2015. Available from:...
Committee on Adolescence Contraception for adolescents
Pediatrics
(2014)- Bayer HealthCare Pharmaceuticals Inc Jaydess® Summary of Product Characteristics. 2015. Available from:...
Cited by (53)
Clinical Assessment of 3 Intrauterine Devices in Adolescent Girls: A Randomized Clinical Trial
2024, Journal of Pediatric and Adolescent GynecologyAn Integrative Review of Extended Use of Intrauterine Devices
2023, Nursing for Women's HealthRelationship of parity and prior cesarean delivery to levonorgestrel 52 mg intrauterine system expulsion over 6 years
2021, ContraceptionCitation Excerpt :Expulsion occurs infrequently after intrauterine device (IUD) placement [1–3], but the reasons for which expulsion occurs for some users and not others remain unknown.
Long-acting drug delivery systems: Applications for sexual and reproductive health
2021, Long-Acting Drug Delivery Systems: Pharmaceutical, Clinical, and Regulatory Aspects
- ☆
Clinical Trial Registration: ClinicalTrials.gov NCT00528112